Targeted therapies for CRC mainly include anti-vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR), epidermal growth factor receptor (EGFR), and multi-target kinase inhibitors, as well as their rare and uncommon targets (Table 1). The gene discussed is EGFR; the disease is colorectal carcinoma.